Kiran Mazumbar shaw fight against Cancer
Wednesday, June 9, 2010
, Posted by Unknown at 5:00 AM
Biocon and HCG group of hospitals announced their partnership to conduct a study to evaluate the potential benefits of BIOMAb EGFR in cervical cancer patients.This unique molecule would take healthcare for cervical cancer patients to a new threshold. BIOMAb EGFR is Biocon’s humanized monoclonal antibody which is approved for the treatment of head and neck cancers in India.
The study will be conducted for six years in various centers of HCG across the country, involving many eminent oncologists and will be in compliance to ICH-GCP guidelines. The participating centers are Bangalore, Mysore, Vijayavada, Ranchi, Cuttack and Nashik.
“This partnership is in light of the unmet need for an effective treatment option for the large number of cervical cancer patients in our country. I see this collaborative model of Biocon’s unique humanized MAb and HCG’s state of the art facilities as a big step towards developing India as a global destination for translational research and cutting edge clinical trials.” said Kiran Mazumdar Shaw, MD, Biocon Ltd.
Ajai Kumar, Chairman and CEO of HCG group of hospitals said, “This HCG-led study will be conducted in a well controlled manner specifically keeping in mind the needs of the Indian patients which vary considerably from those of the West. Most treatment for this disease is currently based on data obtained from the western world. We chose BIOMAb EGFR taking into account the safety profile this molecule has displayed in addition to results obtained in the other studies with this drug”.
Cervical cancer is the most common cancer among women in India and is the primary cause of cancer-related deaths in developing countries. To an estimated annual global incidence of 500,000 cervical cancers, India contributes 100,000, ie. 1/5 of the world burden. Cervical cancer is responsible for more than 280,000 deaths annually worldwide. In India the number of deaths due to cervical cancer is estimated to rise to 79,000 by the year 2010. The cancer mostly affects middle-aged women (between 40 and 55 years), especially those from the lower economic status.Chemo radiotherapy has been shown in several studies to be more effective in terms of overall survival and local control, than radiation therapy alone in the treatment of women with locally advanced carcinoma of the cervix. But still the 2 year progression free survival is around 67% and there is a need for further improvement.
BIOMAb EGFR is being studied globally in various indications like Glioma, NSCLC, Pancreatic cancer, Gastric...
Biography:
Chairman & Managing Director of Biocon Ltd; Felicitated with Padmashri (1989) and Padma Bhushan (2005).
Kiran Mazumdar Shaw is the Chairman & Managing Director of Biocon Ltd, India's biggest biotechnology company. In 2004, she became India's richest woman.
Kiran Mazumdar Shaw was born on March 23, 1953 in Bangalore. She had her schooling at Bishop Cotton Girls School and Mount Carmel College at Bangalore. After doing completing her B.Sc. in Zoology from Bangalore University in 1973, she went to Ballarat University in Melbourne, Australia and qualified as a master brewer.
Kiran Mazumdar Shaw started her professional career as trainee brewer in Carlton & United Beverages in 1974. In 1978, she joined as Trainee Manager with Biocon Biochemicals Limited in Ireland. In the same year, Kiran Mazumdar Shaw founded Biocon India in collaboration with Biocon Biochemicals Limited, with a capital of Rs.10,000. She initially faced many problems regarding funds for her business. Banks were hesitant to give loan to her as biotechnology was a totally new field at that point of time and she was a woman entrepreneur, which was a rare phenomenon.
Biocon's initial operation was to extract an enzyme from papaya. Under Kiran Mazumdar Shaw's stewardship Biocon transformed from an industrial enzymes company to an integrated biopharmaceutical company with strategic research initiatives. Today, Biocon is recognised as India's pioneering biotech enterprise. In 2004, Biocon came up with an IPO and the issue was over-subscribed by over 30 times. Post-IPO, Kiran Mazumdar Shaw held close to 40% of the stock of the company and was regarded as India's richest woman with an estimated worth of Rs. 2,100 crore.
Kiran Mazumdar Shaw is the recipient of several prestigious awards. These include ET Businesswoman of the Year, Best Woman Entrepreneur, Model Employer, Ernst & Young's Entrepreneur of the Year Award for Life Sciences & Healthcare, Leading Exporter, Outstanding Citizen, Technology Pioneer, etc. Government of India also felicitated her with Padmashri (1989) and Padma Bhushan (2005).
Kiran Mazumdar Shaw is the Chairman & Managing Director of Biocon Ltd, India's biggest biotechnology company. In 2004, she became India's richest woman.
Kiran Mazumdar Shaw was born on March 23, 1953 in Bangalore. She had her schooling at Bishop Cotton Girls School and Mount Carmel College at Bangalore. After doing completing her B.Sc. in Zoology from Bangalore University in 1973, she went to Ballarat University in Melbourne, Australia and qualified as a master brewer.
Kiran Mazumdar Shaw started her professional career as trainee brewer in Carlton & United Beverages in 1974. In 1978, she joined as Trainee Manager with Biocon Biochemicals Limited in Ireland. In the same year, Kiran Mazumdar Shaw founded Biocon India in collaboration with Biocon Biochemicals Limited, with a capital of Rs.10,000. She initially faced many problems regarding funds for her business. Banks were hesitant to give loan to her as biotechnology was a totally new field at that point of time and she was a woman entrepreneur, which was a rare phenomenon.
Biocon's initial operation was to extract an enzyme from papaya. Under Kiran Mazumdar Shaw's stewardship Biocon transformed from an industrial enzymes company to an integrated biopharmaceutical company with strategic research initiatives. Today, Biocon is recognised as India's pioneering biotech enterprise. In 2004, Biocon came up with an IPO and the issue was over-subscribed by over 30 times. Post-IPO, Kiran Mazumdar Shaw held close to 40% of the stock of the company and was regarded as India's richest woman with an estimated worth of Rs. 2,100 crore.
Kiran Mazumdar Shaw is the recipient of several prestigious awards. These include ET Businesswoman of the Year, Best Woman Entrepreneur, Model Employer, Ernst & Young's Entrepreneur of the Year Award for Life Sciences & Healthcare, Leading Exporter, Outstanding Citizen, Technology Pioneer, etc. Government of India also felicitated her with Padmashri (1989) and Padma Bhushan (2005).
Currently have 0 comments: